Clinical Efficiency of Metagenomic Next-Generation Sequencing in Sputum for Pathogen Detection of Patients with Pneumonia According to Disease Severity and Host Immune Status
Can Chang,Huan Wang,Lianjun Zhang,Junling Hao,Xiaoning Wang,Yaoyao Wang,Fei Qi,Jingwei Lou,Jiangman Zhao,Junying Dong
DOI: https://doi.org/10.2147/IDR.S419892
2023-09-07
Infection and Drug Resistance
Abstract:Can Chang, 1 Huan Wang, 1 Lianjun Zhang, 1 Junling Hao, 1 Xiaoning Wang, 1 Yaoyao Wang, 2 Fei Qi, 2 Jingwei Lou, 2 Jiangman Zhao, 2 Junying Dong 1 1 Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Heze Branch, Heze, Shandong, 274000, People's Republic of China; 2 Shanghai Zhangjiang Institute of Medical Innovation, Shanghai Biotecan Pharmaceuticals Co., Ltd, Shanghai, 201204, People's Republic of China Correspondence: Junying Dong, Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Heze Branch, Caozhou Road 2888, Heze, Shandong, 274000, People's Republic of China, Tel +86- 13723908695, Email Jiangman Zhao, Shanghai Zhangjiang Institute of Medical Innovation, Shanghai Biotecan Pharmaceuticals Co., Ltd, Zhangheng Road 180, Shanghai, 201204, People's Republic of China, Tel +86- 18817517482, Email Purpose: Severe pneumonia causes the highest mortality rate in immunocompromised patients. This study aimed to investigate the pathogen diagnostic efficacy of metagenomic next-generation sequencing (mNGS) using sputum sample in patients with pneumonia according to patients' disease severity and immune conditions. Patients and Methods: A total of 180 patients suffering from pneumonia were recruited, and sputum samples were collected in duplicate for pathogen detection by both conventional microbiological tests (CMT) and mNGS. Then, the performance of pathogen identification was examined between two methods, according to disease severity and patients' immune status. Results: In comparison to CMT, mNGS had higher positivity rates in all patients with pneumonia (85.0% vs 62.2%, P =9.445e-07). The most commonly detected microorganism in sputum of pneumonia patients was Acinetobacter baumannii (42/180, 23.3%) in bacterum level, Candida albicans in fungus level (44/180, 24.4%), and Human herpesvirus 1 (39/180, 27.5%) in virus level. However, for mNGS results, Candida albicans in 34.9% of positive patients, and Human herpesvirus 1 in 7.7% of positive cases were confirmed as pathogens causing pneumonia. Acinetobacter baumannii detected by mNGS in 75% of positive patients was diagnosed as pathogen of pneumonia. The microorganism profile of sputum mNGS differed according to disease severity and immune status of patients. Pneumocystis jirovecii was more likely to infect immunocompromised patients ( P =0.002). Pseudomonas aeruginosa (14.8% vs 0.0%, P =0.008) and Human herpesvirus 1 (26.1% vs 5.3%, P =0.004) had higher infection rate in patients with severe pneumonia compared with non-severe cases. mNGS had overwhelming advantages over CMT in detecting a lot of microorganisms including Streptococcus pneumoniae, Enterococcus faecium, Pneumocystis jirovecii , and majority of viruses. Conclusion: mNGS is a complementary tool of CMT for detecting suspected pathogens for patients with lower respiratory infections. The interpretation of opportunistic pathogens identified by mNGS is challenging, and needs comprehensive consideration of sequencing data and clinical factors. Keywords: lower respiratory infections, severe pneumonia, immunocompromised patient, conventional microbiological test, metagenomic-next generation sequencing Lower respiratory infections (LRIs) are the world's most deadly communicable disease and ranks fourth as the primary cause of death globally according to the World Health Organization (WHO) 2019 report. 1,2 LRIs include hospital-acquired pneumonia (HAP), community-acquired pneumonia (CAP), bronchiolitis, bronchitis, and tracheitis. 3,4 Immunocompromised patients have a higher risk of experiencing severe pneumonia, that is a major factor in mortality rate of these patients and a primary reason for admission to intensive care units (ICU). 5,6 Fast and accurate verification of the causative pathogens is imperative as it helps avoid empirical misuse of wide-spectrum antibiotics and improves the clinical outcomes of immunocompromised patients with severe pneumonia. 7 Pneumonia is heterogeneous and complex, caused by a broad spectrum of microbes, including bacteria, fungi, mycoplasma, chlamydia, and viruses. 8 Conventional microbiological tests (CMT) are widely used for pathogen identification, which comprises culture-based methods and molecular detection procedures, for example polymerase chain reaction (PCR) and enzyme immunoassay. 9 However, despite the extensive diagnostic workup, the etiology of 19% to 62% of pneumonia patients remains undiagnosed. 10–12 Cul -Abstract Truncated-
pharmacology & pharmacy,infectious diseases